These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 25504751

  • 1. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
    Liu T, Sun Q, Li Q, Yang H, Zhang Y, Wang R, Lin X, Xiao D, Yuan Y, Chen L, Wang W.
    Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
    [Abstract] [Full Text] [Related]

  • 2. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H, Kim Y, Sul JW, Jeong IG, Yi HJ, Ahn JB, Kang JS, Yun J, Hwang JJ, Kim CS.
    Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
    [Abstract] [Full Text] [Related]

  • 3. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
    Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK, Zhu XF.
    PLoS One; 2013 Nov; 8(3):e59879. PubMed ID: 23533654
    [Abstract] [Full Text] [Related]

  • 4. PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair.
    Xie Y, Liu C, Zhang Y, Li A, Sun C, Li R, Xing Y, Shi M, Wang Q.
    PLoS One; 2021 Nov; 16(10):e0258817. PubMed ID: 34665844
    [Abstract] [Full Text] [Related]

  • 5. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
    Mallon R, Feldberg LR, Lucas J, Chaudhary I, Dehnhardt C, Santos ED, Chen Z, dos Santos O, Ayral-Kaloustian S, Venkatesan A, Hollander I.
    Clin Cancer Res; 2011 May 15; 17(10):3193-203. PubMed ID: 21325073
    [Abstract] [Full Text] [Related]

  • 6. Chloroform extract from Sophora Tonkinensis Gagnep. inhibit proliferation, migration, invasion and promote apoptosis of nasopharyngeal carcinoma cells by silencing the PI3K/AKT/mTOR signaling pathway.
    ShuoWang, Song Z, Gong X, Ou C, Zhang W, Wang J, Yao C, Qin S, Yan B, Li Q, Wei K, Hou X, Zhou X, Miao J.
    J Ethnopharmacol; 2021 May 10; 271():113879. PubMed ID: 33524509
    [Abstract] [Full Text] [Related]

  • 7. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY, Wu HC, Wu JE, Huang KY, Yang SC, Chen SX, Tsao CJ, Hsu KF, Chen YL, Hong TM.
    J Exp Clin Cancer Res; 2019 Jul 01; 38(1):282. PubMed ID: 31262325
    [Abstract] [Full Text] [Related]

  • 8. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance.
    Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH, Li Y.
    Cell Death Dis; 2013 Oct 24; 4(10):e875. PubMed ID: 24157869
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pre-treatment with angiotensin-(1-7) inhibits tumor growth via autophagy by downregulating PI3K/Akt/mTOR signaling in human nasopharyngeal carcinoma xenografts.
    Lin YT, Wang HC, Chuang HC, Hsu YC, Yang MY, Chien CY.
    J Mol Med (Berl); 2018 Dec 24; 96(12):1407-1418. PubMed ID: 30374682
    [Abstract] [Full Text] [Related]

  • 12. The effects of PKI-402 on breast tumor models' radiosensitivity via dual inhibition of PI3K/mTOR.
    Gasimli R, Kayabasi C, Ozmen Yelken B, Asik A, Sogutlu F, Celebi C, Yilmaz Susluer S, Kamer S, Biray Avci C, Haydaroglu A, Gunduz C.
    Int J Radiat Biol; 2023 Dec 24; 99(12):1961-1970. PubMed ID: 37389464
    [Abstract] [Full Text] [Related]

  • 13. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.
    Wong CH, Loong HH, Hui CW, Lau CP, Hui EP, Ma BB, Chan AT.
    Invest New Drugs; 2013 Dec 24; 31(6):1399-408. PubMed ID: 23975511
    [Abstract] [Full Text] [Related]

  • 14. Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway.
    Guo S, Zhang J, Wei C, Lu Z, Cai R, Pan D, Zhang H, Liang B, Zhang Z.
    Cancer Chemother Pharmacol; 2020 Jun 24; 85(6):1097-1108. PubMed ID: 32449143
    [Abstract] [Full Text] [Related]

  • 15. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J, Rozengurt E.
    Mol Cancer Ther; 2015 Apr 24; 14(4):1014-23. PubMed ID: 25673820
    [Abstract] [Full Text] [Related]

  • 16. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ, Heo JH, Park JY, Jeong JY, Cho HJ, Park KS, Kim SH, Moon YW, Kim JS, An HJ.
    Gynecol Oncol; 2019 Apr 24; 153(1):135-148. PubMed ID: 30686552
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress.
    Li Q, Ni W, Deng Z, Liu M, She L, Xie Q.
    Fundam Clin Pharmacol; 2017 Jun 24; 31(3):301-310. PubMed ID: 28078787
    [Abstract] [Full Text] [Related]

  • 19. PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma.
    Cao J, Zeng K, Chen Q, Yang T, Lu F, Lin C, Zhan J, Ma W, Zhou T, Huang Y, Luo F, Zhao H.
    Cell Death Dis; 2024 Mar 30; 15(3):237. PubMed ID: 38555280
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models.
    Langdon SP, Kay C, Um IH, Dodds M, Muir M, Sellar G, Kan J, Gourley C, Harrison DJ.
    Sci Rep; 2019 Dec 10; 9(1):18742. PubMed ID: 31822716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.